Pharmacology Study Guide

📖 Core Concepts Pharmacology – scientific study of drugs and their interactions with living systems. Drug vs. Pharmaceutical – a drug is any chemical that alters biology; a pharmaceutical is a drug used for medicinal purposes. Pharmacokinetics (PK) – “what the body does to the drug”: liberation, absorption, distribution, metabolism, excretion (LADME). Pharmacodynamics (PD) – “what the drug does to the body”: receptor binding, signal transduction, dose‑response, therapeutic window. System‑Specific Areas – neuro‑, immuno‑, cardiovascular, renal, endocrine, psychopharmacology each focus on drug effects in a particular organ system. Posology – science of selecting the right dose (amount, frequency, route). --- 📌 Must Remember Half‑life: $t{½} = \dfrac{0.693 \times VD}{Cl{tot}}$ – time for plasma concentration to fall 50 %. Volume of Distribution (VD): $VD = \dfrac{\text{Total amount of drug in body}}{\text{Plasma concentration}}$. Clearance (Cl): volume of plasma cleared of drug per unit time (L · h⁻¹). Bioavailability (F): fraction of administered dose that reaches systemic circulation unchanged. $EC{50}$: concentration that produces 50 % of maximal effect – a measure of potency. Therapeutic Window: concentration range between minimum effective dose and minimum toxic dose. Agonist vs. Antagonist: agonist → activates receptor; antagonist → blocks receptor without activating. Partial Agonist: binds but elicits sub‑maximal response compared with a full agonist. Narrow vs. Wide Therapeutic Index: narrow → careful monitoring required; wide → safer dosing margin. --- 🔄 Key Processes LADME Sequence Liberation: drug released from dosage form (disintegration/dissolution). Absorption: entry into systemic circulation (skin, GI tract, mucosa, lung). Distribution: movement into tissues; influenced by perfusion, protein binding, lipophilicity. Metabolism: mainly hepatic enzymatic conversion (e.g., CYP450) → active/inactive metabolites. Excretion: removal via kidney (urine), bile, breath, sweat. Dose‑Response Relationship Plot dose (x‑axis) vs. effect (y‑axis). Sigmoidal (Hill) curve: $E = \dfrac{E{\max} \cdot [D]^n}{EC{50}^n + [D]^n}$ where n = Hill coefficient. Drug Discovery Workflow Lead identification → SAR analysis → analogue synthesis → pre‑clinical testing → clinical phases I‑III → regulatory approval. Photopharmacology Activation Light of specific wavelength → structural isomerization of photoswitch → on/off drug activity. --- 🔍 Key Comparisons Agonist vs. Antagonist Agonist: binds → receptor conformational change → response. Antagonist: binds → no conformational change → blocks agonist. Full vs. Partial Agonist Full: produces maximal $E{\max}$. Partial: produces $E < E{\max}$ even at full receptor occupancy. Narrow vs. Wide Therapeutic Index Narrow: small safety margin; dose titration critical. Wide: large safety margin; easier dosing. Systemic vs. Process Clearance Systemic: total body elimination (sum of hepatic, renal, extra‑hepatic). Process: clearance from a specific organ or tissue. Photopharmacology vs. Conventional Drugs Photopharma: activity toggled by light → spatial/temporal precision. Conventional: activity fixed after administration. --- ⚠️ Common Misunderstandings “Half‑life = time to eliminate drug” – it’s the time for concentration to drop by half, not complete elimination. “Higher $VD$ = higher efficacy” – a large $VD$ often means extensive tissue binding, not necessarily better effect. “Potency = efficacy” – potency ($EC{50}$) reflects dose needed for effect; efficacy reflects maximal possible effect. “All antagonists are competitive” – antagonists can be competitive, non‑competitive, or irreversible. “Photopharmacology works with any wavelength” – only the specific wavelength matching the photoswitch’s absorption spectrum triggers activation. --- 🧠 Mental Models / Intuition “PK is the journey, PD is the destination.” Visualize a drug traveling through the body (LADME) and then meeting its “address” (receptor) to deliver a message. “Therapeutic window as a safe corridor.” Imagine walking a tightrope: the lower rail = ineffective, the upper rail = toxic; stay centered. “Hill curve steepness = cooperativity.” A steeper curve (higher Hill coefficient) = more cooperative binding → small dose changes cause big effect shifts. “Photopharma as a light switch.” Think of a lamp: flipping the switch (light) toggles drug on/off without changing the wiring (molecule). --- 🚩 Exceptions & Edge Cases Non‑monotonic dose‑response: low and high concentrations can produce reduced effects (U‑shaped curves) due to receptor desensitization or opposite pathway activation. Active metabolites: metabolism can generate a metabolite with equal or greater activity than the parent drug. High plasma protein binding: only the free (unbound) fraction is pharmacologically active; changes in binding can drastically alter effect. CYP450 polymorphisms: genetic variability may turn a normal metabolizer into a poor or ultra‑rapid metabolizer, altering clearance. --- 📍 When to Use Which Choose clearance vs. half‑life for dosing calculations: Use clearance when adjusting dose for renal/hepatic impairment. Use half‑life to determine dosing interval. Select agonist vs. partial agonist therapy: Full agonist when maximal receptor activation is desired (e.g., bronchodilation). Partial agonist when a “moderate” activation is safer (e.g., buprenorphine for opioid dependence). Apply photopharmacology only when: spatial precision is required (e.g., localized tumor) and tissue penetration of activating light is feasible. Use SAR analysis during lead optimization to improve potency, selectivity, or pharmacokinetic properties. --- 👀 Patterns to Recognize LADME bottleneck pattern: a drug with poor oral bioavailability often fails at absorption or first‑pass metabolism. Therapeutic index pattern: narrow index drugs frequently have tight dosing schedules and require therapeutic drug monitoring (e.g., lithium). Receptor family pattern: GPCR drugs often show dose‑dependent bias (G‑protein vs. β‑arrestin pathways). Non‑monotonic curve pattern: U‑shaped dose‑response may hint at receptor desensitization or inverse agonism at high concentrations. --- 🗂️ Exam Traps “A drug with a short half‑life must be dosed frequently.” Trap: ignores formulation strategies (e.g., sustained‑release) that extend effect. “Higher affinity always means higher potency.” Trap: potency also depends on efficacy and receptor density; a high‑affinity partial agonist may have low potency. “All metabolites are inactive.” Trap: many prodrugs are activated by metabolism; some metabolites are toxic (e.g., acetaminophen → NAPQI). “Photopharmacology is only for research.” Trap: emerging clinical trials (e.g., light‑activated anticancer agents) show therapeutic potential. “If a drug is lipophilic, it will cross the BBB.” Trap: BBB transport also requires low molecular weight, low polarity, and lack of efflux transporter substrates. ---